A few months after getting FDA approval for human trials, Neuralink is looking for its first test subjects. The six-year initial trial, which the Elon Musk-owned company is calling “the PRIME Study,” is intended to test Neuralink tech designed to help those with paralysis control devices. The company is looking for people with quadriplegia due to vertical spinal cord injury or ALS who are over the age of 22 and have a “consistent and reliable caregiver” to be part of the study.

The PRIME Study (which apparently stands for Precise Robotically Implanted Brain-Computer Interface, even though that acronym makes no sense) is set to research three things at once. The first is the N1 implant, Neuralink’s brain-computer device. The second is the R1 robot, the surgical robot that actually implants the device. The third is the N1 User App, the software that connects to the N1 and translates brain signals into computer actions. Neuralink says it’s planning to test both the safety and efficacy of all three parts of the system.